ABPI Consultation on the proposed 2021 ABPI Code of Practice for the Pharmaceutical Industry

The Association of British Pharmaceutical Industry (ABPI) and The Prescription Medicines Code of Practice Authority (PMCPA)* launched a consultation on 19 June 2020 for the proposed changes for the 2021 Code of Practice (consultation closing date is 8 September 2020).

The ABPI is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).  The ABPI must ensure that the changes introduced during the recent consolidation of the EFPIA Codes are also reflected in the new 2021 ABPI Code.  The proposals for the new 2021 APBI Code will result in the most significant structural change in nearly 30 years and make a major impact on the way that people interact with the requirements.

The changes are designed to bring the ABPI Code up-to-date and reflect the recent updates made to the 2019 EFPIA Code.  The new EFPIA Code format has been utilised in the design of the proposed 2021 ABPI Code format.

The aim of the ABPI Code of Practice is to ensure that the promotion of medicines by the pharmaceutical industry is carried out within a robust framework, to support high quality patient care.

Once approved the new 2021 ABPI Code will be published by 1 January 2021.  The 2019 Code of Practice will remain in force until 30  June 2021 and the new 2021 Code will come into force on 1 July 2021.


PMCPA Guide to the proposed 2021 ABPI Code of Practice: https://www.pmcpa.org.uk/media/3148/200616-guide-to-the-code-final-190620.pdf

Link to current ABPI 2019 Code of Practice: https://www.pmcpa.org.uk/media/2258/code-of-practice-2019.pdf

* The PMCPA is the self-regulatory body which administers the ABPI Code of Practice for the Pharmaceutical Industry, independently of the ABPI.  It was established by the ABPI on 01.01.1993.

Janet Worrell